Pre-IPO HighTide Therapeutics - Its Outlook in NASH Field Is Not Optimistic, with High Risks
Intercept's failure to obtain FDA approval for NASH drug may cast shadow on HighTide's core product outlook.HighTide's valuation performance is...
468 Views
Legend Biotech Follow-On - A Little Opportunistic. Last Deal Did Well, After a Large Correction
Legend Biotech Corp (LEGN US), a non-wholly owned subsidiary of Hong Kong-listed Genscript Biotech (1548 HK), is planning to raise up to US$250m in...
426 Views
Would the Cheap Versions of Oral COVID-19 Antiviral Bring New Opportunities for Chinese Companies?
Some Chinese companies are allowed to make cheap versions of Merck’s molnupiravir based on the MPP agreement.We analyzed the impact and outlook,...
332 Views
Yichang HEC Changjiang Pharma (1558 HK): Multiple New Products Launches Bring New Opportunities
HEC Pharm is on a new growth path through the launch of diabetes and oral HCV drugs. The company has a rich pipeline of innovative drugs, entailing...
367 Views
China Healthcare Weekly (Nov.12)-Medical Insurance Negotiation,Spring Coil VBP,Valuation Upside Down
This insight mainly analyzed some news circulating about 2021 national medical insurance negotiation results, VBP on spring coil in Hebei and...
254 Views